Sepracor boosts DSP's top line but generics bite at home
This article was originally published in Scrip
The consolidation of fourth-quarter figures for its US acquisition Sepracor boosted Dainippon Sumitomo Pharma's (DSP) top line by ¥28.6 billion ($306 million) in the fiscal year to 31 March.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.